Skip to playerSkip to main content
  • 1 minute ago
An experimental drug doubled the one-year survival rate for patients with advanced pancreatic cancer, offering fresh hope against one of the deadliest cancers.

Read More:
https://www.freemalaysiatoday.com/category/nation/2026/04/16/malaysian-doctor-leads-breakthrough-pancreatic-cancer-trial

Free Malaysia Today is an independent, bi-lingual news portal with a focus on Malaysian current affairs.

Subscribe to our channel - http://bit.ly/2Qo08ry
------------------------------------------------------------------------------------------------------------------------------------------------------
Check us out at https://www.freemalaysiatoday.com
Follow FMT on Facebook: https://bit.ly/49JJoo5
Follow FMT on Dailymotion: https://bit.ly/2WGITHM
Follow FMT on X: https://bit.ly/48zARSW
Follow FMT on Instagram: https://bit.ly/48Cq76h
Follow FMT on TikTok : https://bit.ly/3uKuQFp
Follow FMT Berita on TikTok: https://bit.ly/48vpnQG
Follow FMT Telegram - https://bit.ly/42VyzMX
Follow FMT LinkedIn - https://bit.ly/42YytEb
Follow FMT Lifestyle on Instagram: https://bit.ly/42WrsUj
Follow FMT on WhatsApp: https://bit.ly/49GMbxW
------------------------------------------------------------------------------------------------------------------------------------------------------
Download FMT News App:
Google Play – http://bit.ly/2YSuV46
App Store – https://apple.co/2HNH7gZ
Huawei AppGallery - https://bit.ly/2D2OpNP

#FMTNews

Category

🗞
News
Transcript
00:00A breakthrough in cancer research.
00:03A Malaysian doctor has led a clinical trial in Chicago that could offer new hope for patients with advanced pancreatic
00:10cancer, one of the deadliest forms of the disease.
00:13Dr. M. Devalingam, who heads the study at Northwestern University, said the experimental treatment significantly improved survival outcomes in patients
00:23who typically live less than a year after diagnosis.
00:26The Phase 2 trial found that patients given LRAGlucib alongside standard chemotherapy were twice as likely to survive one year
00:35compared with those receiving chemotherapy alone.
00:38The treatment also reduced the risk of death by 38% in findings published in the journal Nature Medicine.
00:46Devalingam and his team are now preparing for a Phase 3 trial to confirm the results and move the treatment
00:51closer to wider use.
00:53Natasha Bust, FMT.
Comments

Recommended